Mikail E. Abbasov, Ph.D.
Assistant Professor
Pharmaceutical Sciences
Phone (405)271-6593 47471
Office 331
Email mikail-abbasov@ou.edu
Faculty Website https://www.chemikailproteomics.com
Summary
Vision: The vast majority of the human proteome remains inaccessible to traditional drug discovery. Closing this gap requires not only chemical and technological innovation but also reimagined therapeutic modalities that modulate protein function and disease pathways through noncanonical mechanisms. The overarching goal of my research program is to pioneer such modalities to deepen mechanistic insight into disease biology and expand the repertoire of tractable targets that regulate pathophysiology.
Strategy: My laboratory integrates synthesis of structurally complex natural products and stereochemically enriched small molecules with modern mass spectrometry-based chemoproteomic technologies, biochemistry, chemical biology, molecular/cell biology, and functional genomics. This unified approach maps pharmacological tractability directly in native proteomes, assigns cellular targets and binding sites of bioactive compounds, and links covalent engagement to functional outcomes. In practice, we conduct phenotype-to-target campaigns that begin with unbiased cellular activity and culminate in validated, target-assigned chemical probe-protein pairs that inform mechanism-of-action studies and translational lead optimization.
Focus: Unlike traditional covalent drug discovery programs that focus on cysteine residues, our strategy centers on the targeted covalent modification of proteinogenic lysine residues, one of the most prevalent amino acids within the human proteome and crucial to numerous cellular processes. This lysine-centric strategy broadens tractability to protein classes and regulatory nodes that are frequently missed by existing paradigms yet remains compatible with complementary covalent strategies when warranted by biology.
Innovation: We established a multiplexed chemoproteomic platform with optimized probes and accelerated acquisition workflows to profile reactive lysines at scale across diverse biological systems. This capability expedites target identification and site mapping for covalent ligands and supports next-generation modalities including covalent inhibitors/activators, bifunctional degraders, molecular dimerizers, and programmable post-translational control of protein function. Collectively, these advances streamline rapid iteration from chemistry to target assignment to functional validation and have seeded programs spanning cancer biology, host-pathogen interactions, and immunometabolism.
Impact: My research program is designed to deliver mechanistically anchored, target-assigned chemical probes that clarify causal biology and seed translational hypotheses by expanding target and mechanism space beyond established paradigms.
Publications & Presentations
no results
Grants
no results
Awards and Honors
no results
Education
- 1. Degree: Postdoctoral Fellowship. Scripps Research Institute. Date: 2020.
2. Degree: Ph D. Texas A&M University. Date: 2015.
3. Degree: MS. Killgore Research Center at West Texas A&M University. Date: 2009.
4. Degree: BS. West Texas A&M University. Date: 2004.
5. Degree: A.S.. Amarillo College. Date: 2002.
Administrative Assignments
no results